richfool wrote:
The way I see it is that with the OAZN vaccine, there is the slightly increased risk of blood clots in younger women particularly those under 30, the OAZN has a lower efficacy and the OAZN is less effective against the South African and Brazilian mutations.
Where do you see it, please?
My understanding is that it is too early to know the answers to these questions, and that little comparable real world data and testing on hypothesis around this has occurred.